BACKGROUND: The second-generation antipsychotic drug olanzapine is an effective pharmacological treatment for psychosis. However, use of the drug is commonly associated with a range of metabolic side effects, including glucose intolerance and insulin resistance. These symptoms have been accurately modelled in rodents. METHODS: We compared the effects of 3 distinct classes of antidiabetic drugs, metformin (100 and 500 mg/kg, oral), rosiglitazone (6 and 30 mg/kg, oral) and glyburide (2 and 10 mg/kg, oral), on olanzapineinduced metabolic dysregulation. After acutely treating female rats with lower (7.5 mg/kg) or higher (15 mg/kg) doses of olanzapine, we assessed glucose intolerance using the glucose tolerance test and measured insulin resistance using the homeostatic model assessment of insulin resistance equation. RESULTS: Both doses of olanzapine caused pronounced glucose dysregulation and insulin resistance, which were significantly reduced by treatment with metformin and rosiglitazone; however, glucose tolerance did not fully return to control levels. In contrast, glyburide failed to reverse the glucose intolerance caused by olanzapine despite increasing insulin levels. LIMITATIONS: We evaluated a single antipsychotic drug, and it is unknown whether other antipsychotic drugs are similarly affected by antidiabetic treatments. CONCLUSION: The present study indicates that oral hypoglycemic drugs that influence hepatic glucose metabolism, such as metformin and rosiglitazone, are more effective in regulating olanzapine-induced glucose dysregulation than drugs primarily affecting insulin release, such as glyburide. The current model may be used to better understand the biological basis of glucose dysregulation caused by olanzapine and how it can be reversed.
BACKGROUND: The second-generation antipsychotic drug olanzapine is an effective pharmacological treatment for psychosis. However, use of the drug is commonly associated with a range of metabolic side effects, including glucose intolerance and insulin resistance. These symptoms have been accurately modelled in rodents. METHODS: We compared the effects of 3 distinct classes of antidiabetic drugs, metformin (100 and 500 mg/kg, oral), rosiglitazone (6 and 30 mg/kg, oral) and glyburide (2 and 10 mg/kg, oral), on olanzapineinduced metabolic dysregulation. After acutely treating female rats with lower (7.5 mg/kg) or higher (15 mg/kg) doses of olanzapine, we assessed glucose intolerance using the glucose tolerance test and measured insulin resistance using the homeostatic model assessment of insulin resistance equation. RESULTS: Both doses of olanzapine caused pronounced glucose dysregulation and insulin resistance, which were significantly reduced by treatment with metformin and rosiglitazone; however, glucose tolerance did not fully return to control levels. In contrast, glyburide failed to reverse the glucose intolerance caused by olanzapine despite increasing insulin levels. LIMITATIONS: We evaluated a single antipsychotic drug, and it is unknown whether other antipsychotic drugs are similarly affected by antidiabetic treatments. CONCLUSION: The present study indicates that oral hypoglycemic drugs that influence hepatic glucose metabolism, such as metformin and rosiglitazone, are more effective in regulating olanzapine-induced glucose dysregulation than drugs primarily affecting insulin release, such as glyburide. The current model may be used to better understand the biological basis of glucose dysregulation caused by olanzapine and how it can be reversed.
Authors: Robert C Smith; Jean-Pierre Lindenmayer; John M Davis; Erin Kelly; Thomas F Viviano; James Cornwell; Qiaoyan Hu; Anzalee Khan; Sumathi Vaidhyanathaswamy Journal: J Clin Psychiatry Date: 2009-10-06 Impact factor: 4.384
Authors: Frederick E Sieber; Khwaji J Zakriya; Allan Gottschalk; Mary-Rita Blute; Hochang B Lee; Paul B Rosenberg; Simon C Mears Journal: Mayo Clin Proc Date: 2010-01 Impact factor: 7.616
Authors: Araba F Chintoh; Steve W Mann; Loretta Lam; Adria Giacca; Paul Fletcher; Jose Nobrega; Gary Remington Journal: Schizophr Res Date: 2009-01-20 Impact factor: 4.939
Authors: Nicholas M Wallingford; Puspha Sinnayah; Frank P Bymaster; Kishore M Gadde; Ranga K Krishnan; Anthony A McKinney; Ronald P Landbloom; Gary D Tollefson; Michael A Cowley Journal: Neuropsychopharmacology Date: 2008-03-05 Impact factor: 7.853
Authors: Claire Wu; Jessica Yuen; Heidi N Boyda; Ric M Procyshyn; Cathy K Wang; Yahya I Asiri; Catherine C Y Pang; William G Honer; Alasdair M Barr Journal: PLoS One Date: 2014-09-25 Impact factor: 3.240
Authors: Heidi N Boyda; Ric M Procyshyn; Catherine C Y Pang; Erin Hawkes; Daniel Wong; Chen Helen Jin; William G Honer; Alasdair M Barr Journal: PLoS One Date: 2013-01-09 Impact factor: 3.240
Authors: Yueshan Hu; Alan J Young; Erik A Ehli; Dustin Nowotny; Paige S Davies; Elizabeth A Droke; Timothy J Soundy; Gareth E Davies Journal: PLoS One Date: 2014-03-25 Impact factor: 3.240
Authors: Diane H Fredrikson; Heidi N Boyda; Lurdes Tse; Zachary Whitney; Mark A Pattison; Fred J Ott; Laura Hansen; Alasdair M Barr Journal: Front Psychiatry Date: 2014-09-05 Impact factor: 4.157